Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical, Ultrasound, and Predictability Outcomes Following Certolizumab Pegol Treatment (with Methotrexate) in Patients with Moderate-to-Severe Rheumatoid Arthritis: 52-Week Results from the CZP-SPEED Study.
Sarzi-Puttini P, Filippucci E, Adami S, Meroni PL, Batticciotto A, Idolazzi L, De Lucia O, Talavera P, Kumke T, Grassi W. Sarzi-Puttini P, et al. Among authors: kumke t. Adv Ther. 2018 Aug;35(8):1153-1168. doi: 10.1007/s12325-018-0751-8. Epub 2018 Jul 24. Adv Ther. 2018. PMID: 30043210 Free PMC article. Clinical Trial.
Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study.
Burmester G, Nüsslein H, von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, Lendl U, Fricke D, Müller-Ladner U. Burmester G, et al. Among authors: kumke t. Clin Exp Rheumatol. 2019 Sep-Oct;37(5):842-851. Epub 2019 Mar 7. Clin Exp Rheumatol. 2019. PMID: 30873942
Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
van der Heijde D, Gensler LS, Maksymowych WP, Landewé R, Rudwaleit M, Bauer L, Kumke T, Kim M, Auteri SE, Hoepken B, Deodhar A. van der Heijde D, et al. Among authors: kumke t. RMD Open. 2022 Mar;8(1):e002138. doi: 10.1136/rmdopen-2021-002138. RMD Open. 2022. PMID: 35296532 Free PMC article. Clinical Trial.
Certolizumab Pegol Efficacy in Patients With Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSpAnd Study.
Robinson PC, Maksymowych WP, Gensler LS, Hall S, Rudwaleit M, Hoepken B, Bauer L, Kumke T, Kim M, de Peyrecave N, Deodhar A. Robinson PC, et al. Among authors: kumke t. ACR Open Rheumatol. 2022 Sep;4(9):794-801. doi: 10.1002/acr2.11469. Epub 2022 Jun 22. ACR Open Rheumatol. 2022. PMID: 35733363 Free PMC article.
Effectiveness and Safety of Certolizumab Pegol in Axial Spondyloarthritis in a Real-World Setting in Greece: A Sub-Analysis of the Prospective Non-Interventional CIMAX Cohort Study.
Katsifis G, Theodoridou A, Bounas A, Georgiou P, Sfikakis P, Fragiadaki K, Dimitroulas T, Mole E, Bauer L, Kumke T, Hoepken B. Katsifis G, et al. Among authors: kumke t. Mediterr J Rheumatol. 2022 Apr 15;33(Suppl 1):162-172. doi: 10.31138/mjr.33.1.162. eCollection 2022 Mar. Mediterr J Rheumatol. 2022. PMID: 36127922 Free PMC article.
16 results